Definium Therapeutics reports positive Phase 3 results for DT120 in generalized anxiety disorder
DFTX•Definium Therapeutics said it will present positive Phase 3 results for DT120 in generalized anxiety disorder at the NEI Fall Congress on November 7, 2026. The presentation will include findings from the Panorama trial.
1. Congress presentations
Definium Therapeutics will present the Panorama trial’s positive findings in adults with generalized anxiety disorder at the NEI Fall Congress in Colorado Springs, November 5-8, 2026. Encore presentations will cover findings from the Emerge trial in major depressive disorder and the Voyage trial in generalized anxiety disorder, alongside safety data compiled across all three Phase 3 trials; these presentations are scheduled for November 7.
